10 November 2024 in Journal of Medicine and Health Technology
DSDesiana Widityaning Sari
A 41-year-old pregnant woman of Javanese ethnicity attended the outpatient clinic of a private hospital, presented with fifth pregnancy and no living children due to a history of ectopic pregnancy, two times IUFD, and one time neonatal death. The patient also had a history of chronic hypertension and asthma. The examination showed positive IgG Toxoplasma and CMV antibody levels. The patient's blood pressure also never touched the normal limit since the beginning of pregnancy. At the end of pregnancy, she had very high blood pressure and proteinuria. According to WHO Maternal Mortality Rate (MMR) is still very high, where two of the five highest causes are infection and hypertension in pregnancy. High risk pregnancies require special attention in monitoring during pregnancy and management. In a history of bad obstetrical history it is necessary to screen for infection which can be done by antibody serology testing. A positive IgG indicates immunity to the virus, if possible it is necessary to check IgG Avidity to determine whether therapy is still needed or can rely on the immune system that has been formed. Chronic hypertension (Systolic Blood Pressure (SBP) > 140 mmHg and / or Diastolic Blood Pressure (DBP) > 90 mmHg since < 20 Weeks Gestational Age (WGA) until 42 days after delivery). First-line Labetalol and Nifedipine or second-line Methyldopa and Hydrochlorothiazide should be considered depending on the condition and gestational age. If there are signs of preeclampsia, termination should be done if possible, along with antihypertensives and anticonvulsants such as MgSO4.
30 September 2024 in Jurnal Eksplora Informatika
The number of cases and deaths of mothers and babies in Indonesia is increasing, which is mediated by low-risk detection in early pregnancy, and a lack of knowledge resulting in the dissemination of pregnancy-related information tends to be poorly understood. As a solution to this problem, the purpose of this study was to analyze the effectiveness and usability of the Poedji Rochjati Score Card (PRSC) feature on the @hamilku.id Digital Platform based on the Delphi method. Qualitative research methods with technical observations were carried out online by obstetricians and gynecologists. The main focus of this research was usability testing involving 46 pregnant women who used the application and 9 randomly selected respondents. The assessment and evaluation were guided by the Delphi method, which involved two rounds of testing by six obstetricians and gynecologists. The results were descriptively analyzed. The findings showed that pregnant female respondents aged between 17 and 34 years had a higher education level, were dominated by people without jobs/housewives, were domiciled in Sidoarjo, had undergone antenatal care (ANC) ≤ 6 times, and had undergone ≥ 5 pregnancies. According to the PRS, 52.2% of pregnant women were classified as having high-risk pregnancies (HRPs). Based on the evaluation of the application from the usability aspect, 83.3% of the participants stated that the information was comprehensive and that the medical terminology was easy to understand. However, only half of them considered visualization in the form of images or animations to be very helpful in illustrating pregnancy risks. Delphi testing with obstetricians and gynecologists revealed that the digital PRSC features generated positive ratings, indicating that the tool is accurate, informative, easy to understand, and effective at improving the quality of health services. The second round showed an improvement in the quality and relevance of the digital PRSC features, with more diverse feedback from the respondents providing a broader perspective for future research and feature development. As a result, the digital PRSC feature can help individuals precisely and accurately identify pregnancy risks.
30 June 2026 in SSRN Electronic Journal
BackgroundCervical cancer screening coverage remains suboptimal in many developing countries. Although WHO recommends HPV DNA testing, limited trained personnel and inadequate infrastructure hinder implementation. Point-of-care (POC) testing offers a promising solution for low-resource settings. This study evaluated the performance of the STANDARD™ M10 POC platform for hr-HPV detection in urine, self-collected vaginal swabs, and cervical swabs compared to laboratory-based assays.MethodsWe compared the STANDARD™ M10 hr-HPV POC platform with established PCR-based assays (Cobas® 6800 HPV and CerviScan hr-HPV). Sexually active women aged 20–65 years were recruited, including those with histologically confirmed cervical cancer and normal cytology. Paired urine, self-collected vaginal, and clinician-collected cervical swabs were analyzed. Agreement was assessed using positive percent agreement (PPA), negative percent agreement (NPA), overall percent agreement (OPA), and Cohen’s kappa (κ).ResultsA total of 114 participants contributed 341 specimens. For cervical swabs, the STANDARD™ M10 assay demonstrated almost perfect agreement with Cobas® 6800 HPV (PPA 97.14%, NPA 98.18%, κ = 0.953) and CerviScan hr-HPV (PPA 100%, NPA 95.46%, κ = 0.946). Similarly high concordance was observed for self-collected vaginal swabs (κ = 0.964 vs Cobas® 6800 HPV; κ = 0.946 vs CerviScan). Urine specimens showed substantial agreement with CerviScan hr-HPV (PPA 94.60%, NPA 85.94%, κ = 0.837). Concordance was highest for HPV16 and HPV18 detection, with discrepancies mainly involving non-16/18 hr-HPV types and invalid results.ConclusionsThe STANDARD™ M10 molecular platform demonstrates comparable performances to centralized PCR-based methods across multiple specimen types in detecting hr-HPV and supports decentralized cervical cancer screening.